All In MedTech

Device Trial Radar · NCT01430299

Efficacy and Safety of Accell Evo3 Demineralized Bone Matrix (DBM) in Instrumented Posterolateral Lumbar Spine Fusion

Efficacy and Safety of Integra Accell Evo3 Demineralized Bone Matrix Instrumented Posterolateral Lumbar Spine Fusion

Last checked: Nov 20, 2026Latest source record: Jun 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

43

Actual

Start

Jun 2011

Primary completion

Mar 2016

Study completion Oct 2016

Sponsor

Lead sponsor
SeaSpine, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Sep 8, 2011

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for posterolateral spine fusion with a retrospective comparison to a historical patient cohort.

Conditions

  • Stenosis
  • Spondylosis
  • Degenerative Changes

Interventions

  • Demineralized Bone MatrixDevice

    Accell Evo3 in posteriolateral fusion (prospective cohort)

  • rh-BMP2Device

    rh-BMP2 in posterolateral fusion (retrospective cohort)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Radiographic Assessments That Indicate Posterolateral Fusion at 12 Months Post SurgeryTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of CA-Davis, Dept. of Orthopaedics, Adult & Pediatric Spine Surgery

    Sacramento, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.